vindesine
Trade name: Eldisine
Small moleculeexperimental
Vindesine, also termed Eldisine, is a semisynthetic vinca alkaloid derived from the flowering plant Catharanthus roseus. Like the natural and semisynthetic vinca alkaloids derived from this plant, vindesine is an inhibitor of mitosis that is used as a chemotherapy drug. By inhibiting mitosis, vinedsine blocks the proliferation of cells, particularly the rapidly proliferation cells of certain types of cancer. It is used, generally in combination with other chemotherapeutic drugs, in the treatment of various malignancies such as leukaemia, lymphoma, melanoma, breast cancer, and lung cancer. — Wikipedia
Clinical trial activity
39 trials · 52 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
30
Phase 3
15
Phase 4
2
Earliest trial started Oct 1, 1994 (NCT00869284)
Timeline
Indications
Approved for
Studied for
- Burkitt Lymphoma · Phase 2
- Glioma · Phase 3
- Hodgkin Disease · Phase 1/Phase 2
- Immunotherapy · Phase 3
- Leukemia-Lymphoma, Adult T-Cell · Phase 2
- Lung Neoplasms · Phase 3
- Lymphoma · Phase 2
- Lymphoma, B-Cell · Phase 2
- Lymphoma, Follicular · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 3
- Lymphoma, Large-Cell, Immunoblastic · Phase 3
- Lymphoma, Non-Hodgkin · Phase 3
- Lymphoma, T-Cell · Phase 4
- Lymphoma, T-Cell, Peripheral · Phase 2
- Melanoma · Phase 4
- Neuroblastoma · Phase 3
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 3
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 2/Phase 3
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · Phase 3
- Small Cell Lung Carcinoma · Phase 2
- Thyroid Neoplasms · Phase 2
- Tumor Suppressor Protein p53 · Phase 2
Mechanism of action
- TubulinINHIBITOR
Tubulin inhibitor
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1- Mol. weight
- 753.94 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL238071 ↗
- WikipediaVindesine ↗
- ChEMBLCHEMBL3989543 ↗
- ChEMBLCHEMBL219146 ↗
- ChEMBLCHEMBL2105882 ↗
Also known as
- 3-(aminocarbonyl)-o(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
- 3-(aminocarbonyl)-o(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
- 3-carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
- 3-carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
- compound 112531
- compound 112531
- compound 112531
- desacetylvinblastine amide
- desacetylvinblastine amide
- desacetylvinblastine amide
- eldisine
- eldisine
- eldisine
- eldisine
- eldisine
- eldisine
- videsine
- vindelsine
- vindesine
- vindesine
- vindesine
- vindesine
- vindesine
- vindesine
- vindesine
- vindesine sulfate
- vindesine sulfate
- vindesine sulfate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07159620 | Phase 2 | Sep 1, 2025 | Soochow University |
| NCT07168980 | Phase 2/Phase 3 (Phase 3) | Jul 1, 2025 | Central South University, Children's Cancer Group, China, Huazhong University of Science and Technology, Jiao Tong University, Nanjing Medical University, Shandong University, Sichuan University, Soochow University, Tianjin Medical University |
| NCT07004075 | Phase 3 | Jun 30, 2025 | Fosun |
| NCT06918015 | Phase 2 | May 1, 2025 | Chinese Academy of Medical Sciences |
| NCT06713057 | Phase 2 | Dec 1, 2024 | Sichuan University |
| NCT06674096 | Phase 2 | Nov 6, 2024 | Chinese Academy of Medical Sciences |
| NCT06361329 | Phase 3 | Apr 30, 2024 | Zhejiang University |
| NCT06176027 | Phase 1/Phase 2 (Phase 2) | Dec 30, 2023 | Government of China, People's Liberation Army of China |
| NCT06158399 | Phase 2 | Nov 22, 2023 | Chinese Academy of Medical Sciences, Nanjing Medical University, Shanxi Medical University, Sun Yat-Sen University, Xiamen University |
| NCT05963347 | Phase 2 | Aug 3, 2023 | Henan Medical University |
| NCT05777369 | N/A | Mar 31, 2023 | Nanjing Medical University |
| NCT06290817 | Phase 2 | Mar 30, 2023 | Huizhou People's Central Hospital, Nanchang University, Ningbo Medical Center Lihuili Eastern Hospital, Wenzhou Medical University, Zhejiang University |
| NCT05896813 | N/A | Mar 1, 2023 | Nanjing Medical University |
| NCT05809180 | N/A | Jan 4, 2023 | Soochow University |
| NCT05974085 | Phase 2 | Aug 1, 2022 | Chinese Academy of Medical Sciences |
| NCT05040555 | N/A | Aug 30, 2021 | Jilin University, Jinlin University |
| NCT04899570 | Phase 2 | Apr 1, 2021 | Chinese Academy of Medical Sciences, Peking University |
| NCT04221035 | Phase 3 | Nov 5, 2019 | Institut Gustave Roussy |
| NCT04043494 | Phase 3 | Aug 1, 2019 | Deutsche Krebshilfe e.V., University of Munster |
| NCT04026269 | Phase 1/Phase 2 (Phase 2) | Jul 30, 2019 | People's Liberation Army of China |
Showing 20 of 39 trials
Page 1 / 2
Organizations
Research & Development (52)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nanjing Medical University | Academic/Hospital | 6 | 2 | 3 | 2015 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 5 | 4 | 1 | 2021 |
| The Lymphoma Study Association | Academic/Hospital | 5 | 4 | 2 | 1999 |
| Deutsche Krebshilfe e.V. | Academic/Hospital | 4 | 0 | 1 | 2007 |
| Sichuan University | Academic/Hospital | 4 | 1 | 2 | 2015 |
| Central South University | Academic/Hospital | 3 | 0 | 1 | 2015 |
| Children's Cancer Group, China | Academic/Hospital | 3 | 3 | 1 | 2015 |
| Huazhong University of Science and Technology | Academic/Hospital | 3 | 0 | 1 | 2015 |
| Jiao Tong University | Academic/Hospital | 3 | 0 | 1 | 2015 |
| Shandong University | Academic/Hospital | 3 | 0 | 1 | 2015 |
| Soochow University | Academic/Hospital | 3 | 2 | 3 | 2023 |
| Tianjin Medical University | Academic/Hospital | 3 | 0 | 1 | 2015 |
| Amgen | For profit | 2 | 0 | 1 | 1994 |
| People's Liberation Army of China | Government | 2 | 1 | 1 | 2019 |
| University of Lyon | Academic/Hospital | 2 | 1 | 1 | 2005 |
| University of Munster | Academic/Hospital | 2 | 2 | 1 | 2017 |
| Zhejiang University | Academic/Hospital | 2 | 2 | 2 | 2023 |
| Badalona Hospital Germans Trias i Pujol | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Dermatologic Cooperative Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2001 |
| European Lung Cancer Working Party | Academic/Hospital | 1 | 1 | 1 | 2008 |
52 organizations
Page 1 / 3